Copay Coupons May Skew Medicare Part B Reimbursement, GAO Says
Executive Summary
Manufacturer-generated average sales price reports used by CMS to set Part B drug reimbursement doesn’t reflect net price after coupons.
You may also be interested in...
Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need
New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need.
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.
FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.